Novo Nordisk Partners with SKIMS to Pioneer Solutions in Cardiology, Nephrology, and Rare Diseases
Srinagar, December 11, 2024: Novo Nordisk India Pvt. Ltd., a leading global healthcare company, has entered into a strategic partnership with the Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, through the signing of a Memorandum of Understanding (MoU). This collaboration aims to advance clinical trials in India, with a specific focus on addressing unmet medical needs in cardiology, obesity, nephrology, and rare diseases.
The partnership was formally announced in a ceremony attended by prominent dignitaries, including Dr. Mohammed Ashraf Ganie, Director of SKIMS; Dr. Shariq Massodi, Dean of the Medical Faculty at SKIMS; and Dr. Muzaffer Wani, Professor of Nephrology at SKIMS. Together, they highlighted the transformative potential of this collaboration for clinical research and patient care in the region.
Vikrant Shrotriya, Managing Director and Corporate Vice President of Novo Nordisk India Pvt. Ltd. described the partnership as a significant step forward in redefining clinical research in India. “By combining our global expertise in innovative therapeutics with SKIMS’ outstanding medical infrastructure, we aim to create healthcare solutions that bridge gaps in access to advanced medicines. This initiative will deliver life-changing outcomes for patients, particularly those in underserved communities,” said Shrotriya.
Dr. Mohammed Ashraf Ganie emphasized the importance of collaboration for both SKIMS and the region. “This MoU represents a pivotal milestone for clinical research in Jammu and Kashmir. It allows us to leverage Novo Nordisk’s expertise to make groundbreaking contributions to medical science while ensuring our community benefits from world-class healthcare advancements,” he stated.
The three-year MoU is the first of its kind in the region, setting a precedent for long-term collaboration in clinical trials. It combines Novo Nordisk’s cutting-edge advancements in therapeutics with SKIMS’ extensive medical capabilities to explore innovative solutions in key therapeutic areas. The partnership will also focus on capacity building at SKIMS, including clinical research training, provision of project-related equipment, and strengthening the skills of the research team.
Additionally, SKIMS will facilitate patient participation in trials, ensure their safety and convenience, and expedite approval processes, reinforcing its role as a cornerstone of medical research in the region.
This groundbreaking collaboration between Novo Nordisk India and SKIMS is expected to reshape the clinical research landscape in India, especially in Jammu and Kashmir. By integrating global innovation with local expertise, the partnership aims to deliver transformative outcomes, improve healthcare accessibility, and ensure life-saving treatments reach the people who need them most.
Sher-i-Kashmir Institute of Medical Sciences, established by an Act of the Jammu and Kashmir Legislature in 1983, is a premier postgraduate institute dedicated to research, education, and patient care. Recognized as a Deemed University, SKIMS serves as a hub for advanced medical studies and healthcare in the region.
Novo Nordisk India Pvt. Ltd., headquartered in Bengaluru, is the Indian affiliate of Novo Nordisk A/S, a global leader in healthcare founded in Denmark in 1923. The company focuses on pioneering innovative treatments for diabetes, obesity, and other chronic conditions. With a workforce of over 69,000 across 80 countries, Novo Nordisk markets its products in approximately 170 nations, continuously striving to defeat chronic diseases through research, accessibility, and care.
This collaboration not only sets the stage for groundbreaking medical advancements but also demonstrates the potential of public-private partnerships in driving healthcare innovation, ensuring a brighter future for patients in Jammu and Kashmir and beyond.
